Author Archives: donttradeourlivesaway

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018 Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional … Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

Intellectual Property rules stand amended

Source: The Hindu | July 02, 2018 Some powers with Customs revoked The Union Ministry of Finance has amended Intellectual Property rules to revoke the power vested with Customs authorities to seize imported products based on complaints of patent infringement. … Continue reading

Posted in IPR Enforcement, IPR policy, Patent infringement | Leave a comment

The switch from patents to state-dependent prizes for technological innovation

by Hwan C. Lin, Journal of Macroeconomics Volume 50, December 2016, Pages 193-223 Highlights •Examine the intertemporal bounty (IB) system as an alternative to patents. •The IB system rewards innovation with a bounty claim to state-dependent prizes (called “intertemporal bounties”) over time. … Continue reading

Posted in Innovation, Patent, Patent examination system, Uncategorized | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

Patient Advocacy Successes in Fight for Medicines

by Fran Quigley, Health & Human Rights Journal | June 26, 2018 Access to essential medicines is a well-established component of the human right to health, but it is a right that remains elusive for millions of people across the globe. The … Continue reading

Posted in Access to Medecines, Biologics/Biosimilars, Cancer, Hepatitis C, Uncategorized | Leave a comment

Transparency in drug pricing an important goal: Dutch health minister

By Rema Nagarajan, The Times of India | June 21, 2018 Netherlands health minister Bruno Bruins was in India recently to promote investments in life sciences and health with affordable healthcare being a key concern for both countries. Bruins spoke to the Times … Continue reading

Posted in Drug prices, Uncategorized | Leave a comment